NDATOPICALCREAM
Approved
Aug 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
BETAMETHASONE VALERATE (betamethasone valerate) by Sandoz is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. Approved for atopic eczema, hand eczema, psoriasis. First approved in 1983.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Betamethasone valerate is a topical corticosteroid cream that reduces inflammation, itching, and redness through anti-inflammatory and vasoconstrictive mechanisms. It is used to treat various dermatological conditions affecting the skin. The drug works by binding to corticosteroid receptors and suppressing inflammatory responses in the epidermis and dermis.
$0.004BPart D
LOE ApproachingProduct approaching loss of exclusivity with modest spending signals a mature, stable franchise managed by a lean team focused on maintenance and generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications (3)
Worked on BETAMETHASONE VALERATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.